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Personalized medicine is emerging in both clinical practice and clinical trials. “Precision” 
medicine not only promises improved safety and efficacy but also lowered cost in clinical 
practice and clinical trials. In 2015, President Obama launched the Precision Medicine Initiative. 
This initiative requires close collaboration among clinicians, researchers, and biostatisticians.  
Enrichment design is an important strategy for increasing study efficiency in personalized 
medicine. Enrichment clinical trial designs involve identifying high-risk patients and choosing 
patients most likely to respond to treatment. In this dissertation, we have developed and applied 
parametric and non-parametric models to the following specific problems:  1) identifying high 
risk patients using Classification and Regression Trees (CART) model; 2) using Bayesian 
distributional approach and finite mixture normal model to improve trial efficiency in a rare 
endpoint scenario; 3) using dynamic linear normal model in enrichment trial designs with ordinal 
risk subgroups. The topics we discussed in this dissertation form a self-contained system within 
the enrichment clinical trial design structure. Identifying high risk patients and efficient 
statistical models are two major components in enrichment designs. However, the application of 
the models we discussed is far beyond the scope in this dissertation. Using CART to identify 
high risk subpopulations can overcome the incapacity of logistic regression models in revealing 
unknown interaction effects. A distributional approach using finite mixture normal model 
provides a flexible model design to fit strongly skewed data. Dynamic linear normal model in the 
enrichment trial design shows to be more efficient and robust compared to previously studied 
designs because it locally smoothes the trend. All these methods help us to accurately identify 
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Chapter 1 : Introduction  
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Modern medicine has evolved from broad-spectrum medical care to targeted therapeutics. 
Patient populations are heterogeneous. Characteristics vary between individuals, such as 
demographics, life style, environments, genetic variants, and etc. These varied characteristics can 
potentially modify the treatment effects on different individuals or subsets of patient populations. 
On one hand, people with some characteristics are more susceptible to certain disease. It is 
important to identify the target populations. The first step of quality care is to clearly define the 
target population according to variables such as age, gender, genetics, specific medical data, and 
etc. Identification of patients at higher risk of a certain disease or disease stage can help us to use 
resources efficiently and improve patients’ quality of life. On the other hand, quality care 
requires identifying the most appropriate treatment strategies for the different populations. 
Personalized medicine, which aims to match patient subpopulation to the most beneficial 
treatment, is more ethical and efficient. FDA has been pushing for personalized medicine for a 
long time. In January 2015, President Obama launched the Precision Medicine Initiative, 
including establishing a national database of the genetic and other data of one million people in 
the United Sates. This is a new research effort to tailor treatment and prevention strategies to 
individuals’ unique characteristics (White House, 2015). Targeted therapeutics enables 
physicians to select treatments that improve patients’ health status and reduce exposure to 
adverse effects. 
The concept of personalized medicine not only promises to improve safety and efficacy 
in clinical practice, but also to lower health care cost through early-detection, prevention, 
accurate risk assessments and efficient care delivery (Jakka & Rossbach, 2013). Personalized 
medicine also has a potential to lower costs in clinical trials. Cost containment in clinical trials is 
another prominent concern in both private and public sectors. The average cost of clinical trials 
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across all therapeutic areas was around $4 million for Phase I trials, $13 million for Phase II 
trials, and $20 million for Phase III trials (U.S. Department of Health and Human Services, 
2014). Phase III trials is the most expensive component among the pre-approval trial stages, yet 
the combined success rate at Phase III and submission has fallen to about 50% in recently years 
(Arrowsmith, 2011). Enrichment on subpopulations that may be more responsive to treatments 
can improve the chance of trial success. In 2012 FDA issued a draft guidance to facilitate 
enrichment designs (U.S. Food and Drug Administration, 2012). The purposes of enrichment 
designs include:1) decreasing heterogeneity; 2) identifying high-risk patients; and 3) choosing 
patients most likely to respond to treatment (U.S. Food and Drug Administration, 2012).
 
Statistical model choice in the health care arena need to accommodate the evolution of 
personalized medicine. By definition, a statistical model is generated from observed or 
experimental data and is a simplification of reality. Statistical models can be used for description, 
prediction, or causal analysis (Maathuis, 2007). These usages are not necessarily mutually 
exclusive (Maathuis, 2007). What good are models and what models are good (Schnerider, 
1993)? These are two fundamental questions in statistical research. Does the model describe the 
reality concisely? Does the model make predictions accurately? Does the model have strong 
capability to identify causal relationships? These naturally become the criteria to determine 
whether the model is good or not. 
This dissertation is trying to explore statistical models, using both parametric and non-
parametric approaches, under the personalized medicine framework. This dissertation is 
composed of three individual studies: the first study discussed methods to identify high-risk 
subpopulations; the second study focused on selecting efficient statistical models in clinical trials 
using a fixed Bayesian design; and the third study explored methods to identify the most 
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beneficial subpopulation in clinical trials, under a Bayesian enrichment design framework. These 
three studies form a self-contained research topic within the personalized medicine paradigm. 
The intrinsic relationship of these three studies can be described by the following vendor 
diagram: 
 
Figure 1.1: The relationship of the three individual studies 
 
In the following chapters, parametric or non-parametric models will be developed and 
evaluated. In chapter 2, traditional logistic regression model and classification and regression 
tree (CART) model are compared, and applied to a study to identify high-risk populations in 
alternative tobacco products use. Logistic regression models are the most commonly used 
method to identify important factors for binary responding variables. Logistic regression model 
was developed by David Cox in 1958 (Cox, 1958). Dr. Frank E. Harrell’s book “Regression 









Analysis” (Harrell, 2001) is the mostly cited book in logistic regression model selection. In 
Chapter 2, a model selection strategy recommended by Dr. Harrell is applied to narrow down 
potential models and then AIC is used as the criterion to determine the final model. Data is 
divided into independent training and validation samples. The final model is built upon the 
training data. A hold-out validation is performed to analyze the goodness-of-fit of the final 
regression model, and to check whether the model’s predictive ability deteriorates substantially 
when applies to the validation data. Classification and regression trees (CART) model is another 
strategy to identify target subpopulations. CART is a data-driven, machine learning method that 
does not assume any specific form of the model such as individual variables, interaction 
relationships, and etc. In problems that no priori specified interaction term exists, CART is 
informative, efficient, and straightforward. This chapter compares and discusses the 
characteristics of these two methods. All analysis is done using SAS version 9.3 and SAS 
Enterprise Miner version 12.3. 
In the third chapter, a model selection problem is discussed in a fixed Bayesian clinical 
trial design framework. The specific issue is that clinicians are interested in a binary outcome 
while the data is collected in a continuous form. Preterm birth (gestation age <37 weeks) and 
earliest preterm birth (gestation age <34 weeks) are clinically important outcomes while 
gestation age is collected in a continuous form. Docosahexaenoic acid (DHA) supplementation is 
a provocative strategy to reduce early preterm delivery (Carlson et al., 2013). Preterm birth and 
earliest preterm birth are rare events so the distribution of gestational age has substantially 
negative skewness. The traditional method is dichotomizing gestational age and then using 
binomial distribution for the dichotomized outcomes. It is widely accepted that pre-
dichotomizing loses information and results in reduced power. Distributional method is another 
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way to gain inference on dichotomized outcomes while retaining statistical power from a 
continuous distribution (Peacock, Sauzet, Ewings, & Kerry, 2012). Gestational age data has 
substantially negative skewness therefore a transformation as log(C-x), where x is gestational 
age data and C is a constant great than x, is a reasonable transformation that normalizes the data 
(Hoaglin, Mosteller, & Tukey, 1983). However, this transformation could introduce a big bias. A 
three-component finite mixture normal model is proposed in this chapter because this 
distribution fits the gestational age data well. In this chapter, dichotomized model, logarithmic 
transformation model, and finite mixture normal model are compared through simulations. In 
simulation studies, we can tune and obtain desirable operating characteristics such as Type I 
Error rate, and evaluate models through Mean Squared Error (MSE) and power. The three 
models are applied to two completed clinical trials and the results are compared by checking 
their bias and standard deviations. In this chapter, simulations and analysis are done using 
Openbugs and R 3.1.1.  
Chapter 4 discusses a topic that is a combination of identifying target populations and 
efficient clinical trial designs, namely enrichment trial designs. Classifying patient populations 
into different risk levels not only helps us to understand the target population, but also introduces 
opportunities to improve the trial efficiency, thus lower the costs of clinical trials. This chapter 
starts with a scenario that subgroup populations can be classified and ordered by their risk levels. 
This chapter continues to examine the effect of DHA supplementation on preterm birth rate, with 
subgroup effects specifically discussed. To improve the power in enrichment clinical trials, this 
chapter applies two approaches: using informative priors and selecting powerful models. 
Informative priors are obtained through meta-analysis that includes nine clinical trials across the 
world. This chapter compares four different statistical models: 1) logistic model which is not 
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flexible and assumes a constant relationship between log odds and risk levels; 2) independent 
model in which no information borrowing across subgroups but the model still borrows 
information from the informative prior distribution; 3) hierarchical model which borrows 
information from informative priors and across groups, assuming exchangeability; and 4) 
dynamic linear model which borrows information from informative priors and across groups, not 
assuming exchangeability. Overall Type I error rate is calibrated in simulations and then 
subgroups’ Type I error rate and power, including the power to capture the most benefited group, 
are compared. Simulations are done using R 3.2.2 and Openbugs. 
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Background: Other forms of tobacco use are increasing in prevalence, yet most tobacco control 
efforts are aimed at cigarettes. In light of this, it is important to identify individuals who are 
using both cigarettes and alternative tobacco products (ATPs). Most previous studies have used 
regression models. We conducted a traditional logistic regression model and a classification and 
regression tree (CART) model to illustrate and discuss the added advantages of using CART in 
the setting of identifying high-risk subgroups of ATP users among cigarettes smokers. 
Methods: The data were collected from an online cross-sectional survey administered by Survey 
Sampling International between July 5, 2012 and August 15, 2012. Eligible participants self-
identified as current smokers, African American, White, or Latino (of any race), were English-
speaking, and were at least 25 years old. The study sample included 2,376 participants and was 
divided into independent training and validation samples for a hold out validation. Logistic 
regression and CART models were used to examine the important predictors of cigarettes + ATP 
users.  
Results: The logistic regression model identified nine important factors: gender, age, race, 
nicotine dependence, buying cigarettes or borrowing, whether the price of cigarettes influences 
the brand purchased, whether the participants set limits on cigarettes per day, alcohol use scores, 
and discrimination frequencies. The C-index of the logistic regression model was 0.74, 
indicating good discriminatory capability. The model performed well in the validation cohort 
also with good discrimination (c-index=0.73) and excellent calibration (R-square=0.96 in the 
calibration regression). The parsimonious CART model identified gender, age, alcohol use score, 
race, and discrimination frequencies to be the most important factors. It also revealed interesting 
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partial interactions. The c-index is 0.70 for the training sample and 0.69 for the validation 
sample. The misclassification rate was 0.342 for the training sample and 0.346 for the validation 
sample. The CART model was easier to interpret and discovered target populations that possess 
clinical significance.  
Conclusion: This study suggests that the non-parametric CART model is parsimonious, 
potentially easier to interpret, and provides additional information in identifying the subgroups at 
high risk of ATP use among cigarette smokers.  
 

















2.1 Background  
Recent years have witnessed increased tobacco control policies at both the state and 
national level (American Nonsmokers' Rights Foundation, 2013; Congress, 2009; Orzechowski 
& Walker, 2011). Most of these efforts are aimed at cigarette smoking (American Nonsmokers' 
Rights Foundation, 2013). The net effects of these policies include decreased cigarettes 
consumption, as well as a shift in the type of tobacco products used (CDC, 2012; Kasza, Bandal-
Travers, & O'Connor, 2014). 
 
The use of alternative forms of tobacco products (ATPs), such as 
large cigars, little cigars, cigarillos, pipes, hand-rolled cigarettes, smokeless tobacco, and 
hookahs, are increasing in prevalence (Campbell, Bozec, McGrath, & Barrett, 2012; McGrath, 
Temporale, Bozec, & Barrett, 2011). About 8%-38% of U.S. daily smokers and as many as 44% 
of non-daily smokers (smoke on some but not all days) are ATP users (Backinger et al., 2008; 
Bombard, Pederson, Nelson, & Malarcher, 2007; Campbell et al., 2012; Kasza et al., 2014; 
McGrath et al., 2011; Popova & Ling, 2013), defined as anyone who uses cigarettes and 
alternative forms of tobacco. These tobacco products have been promoted as less addictive and 
less harmful than cigarettes (Jolly, 2008; Page & Evans, 2003). Nevertheless, data suggest that 
use of these products could be associated with higher nicotine dependence and may contribute to 
increased risks for diseases caused by tobacco, such as cancer and heart disease (Djordjevic & 
Doran, 2009). 
 It is of utmost importance to identify individuals who are at high risk of using both 
cigarettes and ATPs. Research subjects in previous studies have been predominately White 
(Backinger et al., 2008; Bombard, Pederson, Koval, & O'Hegarty, 2009; Bombard et al., 2007; 
Richardson, Xiao, & Vallone, 2012) and most existing studies have used traditional regression 
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approaches to identify important factors associated with ATP use. Although regression methods 
can test a priori specified interaction effects, it lacks the ability to capture unspecified, complex 
inter-relationships across factors. Classification and Regression Trees model (CART) can 
address these limitations by revealing unspecified inter-relationships through an easily 
interpretable tree diagram. Few studies have applied CART modeling to tobacco research (Piper, 
Loh, Smith, Japuntich, & Baker, 2011; Swan, Javitz, Jack, Curry, & McAfee, 2004). In this 
paper we used data from a cross-sectional survey of smokers and conducted the most commonly 
used logistic regression method and relatively underused CART method, and described the 
strength and limitations of these two statistical approaches in identifying cigarette smokers at 
highest-risk for ATP use.  
2.2 Methods  
2.2.1 Study population   
The data was collected through a cross-sectional survey administered through an online 
panel survey service, Survey Sampling International (SSI), between July 5, 2012 and August 15, 
2012. Ethical approval was granted by the University of Minnesota Institutional Review Board. 
Participants were presented with a written informed consent page prior to completing the 
screener. Only participants who indicated their consent were directed to the study 
questions. Eligible participants self-identified as current smokers, African American, White, or 
Latino (of any race), were English-speaking, and were at least 25 years old. The study sample 
contained 2,376 participants balanced by the three racial/ethnic groups across smoking 
frequencies (daily and nondaily smoking): 794 African Americans, 786 Latinos, and 796 whites. 
Among them, 1,220 participants (51.35%) were cigarettes + ATP users who used both cigarettes 
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and other tobacco products and 1,156 (48.65%) were cigarettes-only users. Variable domains in 
this study included: demographics, tobacco characteristics, cost concerns, harm reduction efforts, 
and psychosocial variables. There was minimal missing data, about 4.3% subjects were missing 
one variable (income), and therefore imputation was not necessary. Chi-square tests were used to 
test the unadjusted effects of categorical variables and T-tests were used to test continuous 
variables (Table 2.1). 
2.2.2 Training and validation data sets  
The large sample size allowed for the use of a hold-out validation to obtain independent 
training and validation data sets (Harrell, 2001; Larson, 1931; Mosteller & Wallace, 1963; 
Refaeilzadeh, Tang, & H., 2008; Ruggeri, Kenett, & Faltin, 2008 ). The data was partitioned by 
random sampling, stratifying by cigarettes + ATP use and race/ethnicity to ensure the balance we 
designed. Training sample contained 1,584 participants (two thirds of the sample) and was used 
to derive the model. The remaining data contained 792 participants (one third of the sample) and 
were used to evaluate the predictive ability of the final model. The training and validation 
samples were compared to ensure the differences between the two were negligible (Table 2.2). 
2.2.3 Analysis  
Logistic regression.  Logistic regression is a traditional way to identify important factors 
for binary outcomes. The Akaike Information Criterion (AIC) is widely recommended as a 
model selection criterion (Harrell, 2001). To avoid the technical difficulty of comparing AICs 
from all possible variable combinations, we followed a model selection strategy recommended 
by Frank E. Harrell to trim the potential models
 
(Harrell, 2001) and then picked the minimal AIC 
model from the potential models as the final model. The selection process started with all 
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potential factors. Predicted values from the logistic regression were then regressed on all 
covariates, with the model explaining 100% of the variance. Backward selection based on 𝑅2 
was used to select a parsimonious set of variables. The contribution of each covariate in the 
multivariable model was ranked, and variables with the smallest contribution to the model were 
sequentially eliminated. This iterative process continued until further variable elimination led to 
a greater than 5% loss in model prediction, as compared with the initial model. The remaining 
covariates comprised the parsimonious model and explained over 95% of the variance of the full 
model. Finally, we compared AIC values of neighborhood models around the model we obtained 
in the last step and the minimum AIC model was selected as the final model. This selection 
strategy supports inclusion of only variables that provide incremental prognostic value, avoids 
over-fitting, and maximizes the potential usefulness of the model. Besides this model selection 
strategy, we examined backward selections based on p-value with 0.15 as the threshold to enter 
and 0.05 as the threshold to stay in the model. Both approaches identified the same model.  
Predicted values using the model estimates from the training cohort were generated for 
the validation cohort and the c-index was then calculated based on the proportion of 
concordance.  The predicted values were ranked and cut into deciles. The calibration plot was 
graphed comparing the average predicted probabilities with the observed average probabilities. A 
calibration regression on observed mean probabilities was performed using predicted mean 
probabilities to check the strength of correlation between the predicted and the observed average 
probabilities across deciles. 
Classification and Regression Tree (CART) Model. Although the logistic regression 
model provides knowledge of important profile characteristics, it lacks the ability to identify 
unknown, and therefore, unspecified interaction effects. The interpretation of parameter 
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estimates is based on the fact of controlling for all other covariates.  To address these problems, 
we built Classification and Regression Tree models (CART) in SAS Enterprise Miner version 
12.3 (Gordon, 2013; Loh, 2011). CART is a nonparametric method that identifies mutually 
exclusive and exhaustive subgroups. Members within each subgroup share the same 
characteristics that influence the probability of belonging to the interested response group 
(Lemon, Roy, Clark, Friedmann, & Rakowski, 2003).
 
CART produces a model structure that 
resembles an upside-down tree. The tree starts with the parent node, and the parent node contains 
the entire population. The CART algorithm examines all possible independent variables 
according to a predetermined splitting rule and divides the parent node into two child nodes; the 
child nodes can be further divided into more child nodes. There are many splitting rules, and they 
all begin with defining the impurity of a node (Lemon et al., 2003). The impurity function 
measures the extent of difference/similarity for a node containing data points from possible 
different classes. A node that has no impurity would have no variability (e.g. all cigarettes-only 
smokers, or all cigarettes + ATP smokers). The highest impurity is achieved when p(k|t)=0.5, 
where p(k|t) is defined as the conditional probability of belonging to class k given in node t.  
Although the impurity functions may vary, all splitting rules select the split that has the largest 
difference between the impurity of the parent node and a weighted average of the impurity of the 
two child nodes (Lemon et al., 2003). The Gini splitting rule was recommended most for binary 
outcomes (Gordon, 2013).
 








) + 𝑃𝑙 ∑ 𝑝







p(k|t): conditional probability of dependent variable= k given node t 
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subscript p: parent node 
subscript r: child right node 
subscript l: child left node 
𝑃𝑙: probability in the left child node 
𝑃𝑟: probability in the right child node (note: 𝑃𝑙 + 𝑃𝑟 = 1) 
𝑥𝑗
𝑅: best splitting value of variable 𝑥𝑗 
M: number of potential independent variables 
K:  level of dependent variables. For binary outcomes, K=2 
The larger the value of the improvement in impurity function, the greater difference 
between the two child nodes with respect to the prevalence of the dependent measure. The 
CART procedure selects the independent variable and the splitting cutoff of the continuous 
independent variable to maximize the improvement at each step. The tree grows as child nodes 
are divided into more child nodes. The terminal nodes are where predictions and inferences are 
made.  
It is clear that different samples would produce different trees. One common way to 
assess how different the trees could be is using training and validation samples. To facilitate 
comparisons, the same set of training and validation samples were used in logistic regression 
model and CART model. In CART model, misclassification rates from both the training sample 
and the validation sample were compared to ensure the model is stable. 
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The maximum tree with the minimum misclassification error was examined and the 
misclassification error graph showed that it contained insignificant nodes, which reduced the 
misclassification error marginally but increased the complexity greatly.  A popular stopping 
strategy was applied by predefining the minimum number of points in the terminal node to 
control the size of the tree (Lemon et al., 2003). The minimum node size was set to be 10% of 
the training sample size or about 150 subjects in our study. Models were assessed to identify a 
parsimonious tree that produces non-trivial results with acceptable misclassification rates. 
2.3 Results  
2.3.1 Logistic regression model.   
The final model consisted of nine variables (Table 2.3). Males had the strongest 
association with being a cigarettes + ATP user vs. cigarettes-only user (adjusted OR 2.66, 95% 
CI 2.12 – 3.33). African Americans and Latino were more likely to be cigarettes + ATP users 
compared to whites (adjusted OR 1.58, 95% CI 1.21 – 2.07 and adjusted OR 1.52, 95% CI 1.16 – 
1.99, respectively). Individuals with higher nicotine dependence were more likely to be 
cigarettes + ATP users (adjusted OR 1.51, 95% CI 1.20 – 1.90). Participants who buy their 
cigarettes were less likely to be cigarettes + ATP users compared to those who borrow cigarettes 
from others (adjusted OR 0.617, 95% CI 0.49 – 0.78).  Individuals who were more sensitive to 
the price of cigarettes were more likely to be cigarettes + ATP users (adjusted OR 1.43, 95% CI 
1.14 -1.79). Individuals who set limit on cigarettes per day were more likely to be cigarettes + 
ATP users (adjusted OR 1.30, 95% CI 1.04 – 1.62). Individuals with higher alcohol scores were 
more likely to be cigarettes + ATP users (adjusted OR 1.10, 95% CI 1.064-1.145). Older people 
were less likely to use cigarettes + ATPs (adjusted OR 0.97, 95% CI 0.96-0.98). Higher 
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discrimination scores were associated with higher probability of using cigarettes + ATPs 
(adjusted OR 1.03, 95% CI 1.01 – 1.05).  The C-index of the final model was 0.74, indicating 
good discriminatory capacity (Figure 2.1). 
 
Figure 2.1: Results from logistic regression on the training sample: ROC curve 
 
2.3.2 Model validation   
Participants were similar in terms of all profile characteristics (Table 2.2), except that 
participants in the validation cohort smoked about 1 cigarette per day less than the training 
cohort (10 vs. 9, p=0.009).The model performed well in the validation cohort with good 
discrimination (c-index=0.73) and excellent calibration with an intercept of 0.018 (p-value for 
difference from 0 = 0.65) and a slope=0.96 (p-value for difference from 1= 0.58). The R-square 
for the calibration regression was 0.96 and the Pearson correlation coefficient was 0.98 (p-





Figure 2.2: Results of calibration from validation sample: calibration plot 
2.3.3 Classification and Regression Tree (CART) Model.    
Figure 3 shows the final tree results using the stopping rule of minimum node size no less 
than 150. The same independent training and validation samples were used as in the logistic 
regression. The misclassification rate was 0.342 for the training sample and 0.346 for the 
validation sample. The C-index was 0.70 for the training sample and 0.69 for the validation 
sample.  
Males were more likely to be cigarettes + ATP users, especially when they were 
moderate to heavy drinkers (alcohol use score> 2). A male with a 3 or higher alcohol score had 
73.5% probability of being a cigarettes + ATP user. Females were less likely to be cigarettes + 
ATP users, especially when they were older. Female participants aged 46 or older had a 29.0% 

































probability of being cigarettes + ATP users. Among females age 45 years or younger, Latino and 
African Americans were more likely to be cigarettes + ATP users compared to whites. 37.2% of 
White females aged 45 years or younger were cigarettes + ATP users. Latino and African 
American females aged 45 or younger, who also experienced greater discrimination were more 
likely to be cigarettes + ATP users, about 62.2% probability if their discrimination score was 
greater than 6 (Figure 2.3). Interestingly, age, race, and discrimination effects that impacted 
female participants did not play important roles for males. Alcohol scores increased the risk of 
cigarettes + ATP use for males but were not important for females. These indicated informative 
interaction patterns to examine the profile characteristics of cigarettes + ATP users.
 
Figure 2.3: Classification and Regression Tree model for predicting Cig + ATP users 
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2.4 Limitations  
A hold-out validation strategy was used in this study to obtain independent training and 
validation datasets. The reduced data can result in an enlarged variance. Although this method is 
reasonable in this study because the sample size is large, other validation strategies, such as k-
fold cross validation, which uses overlapped training data, may achieve more accurate 
performance estimation. We used a method suggested by Harrell (2001)
 
(Harrell, 2001) to trim 
potential models and then compared AIC of these potential models to obtain the final model. 
Other model selection strategies, such as LASSO and ridge regression were not compared with 
this method.  
2.5 Discussion  
The CART model identified the five most important factors: gender, alcohol scores, age, 
race, and discrimination scores. The logistic regression model identified nine variables: the same 
five as the CART model, and additionally, whether the participant buys or borrows cigarettes 
from others, whether the participant limits cigarettes per day, price influences, and nicotine 
dependence. Therefore, the logistic regression model expanded the variable pool from the CART 
model. 
The logistic regression model results in higher C-index than the CART model (0.74 
versus 0.70 for the training sample and 0.73 versus 0.69 for the validation sample). However, the 
C-index from the CART model was not directly comparable to that in the logistic regression 
model because the classifiers varied across different subgroups in the CART model due to partial 
interaction effects.  On the other hand, logistic regression models lack the ability to identify 
unspecified, complex inter-relationships between factors. In studies where interaction effects are 
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unclear, it is impractical to test all potential interaction effects in logistic regression models. 
However, there might be potential inter-relationships, especially among demographic, 
psychosocial, and economic factors. Even if the logistic regression model achieves good model 
fit, we could still miss interaction effects that are significant to clinical practice. CART analysis 
is efficient to address these problems and it is easy to perform with available statistical software. 
It has great flexibility of building a model that can be easily interpreted through pictorial 
illustration, without pulling in too much complexity. CART can be considered as complementary 
to logistic regression models and the result from CART revealed clearly classified high-risk 
populations of ATP use among cigarette smokers. 
2.6 Conclusions  
The growing trend of ATP use could ultimately cut down the effect of tobacco control 
efforts that we have seen in recent years. Compared to the traditional logistic regression model, 
our CART model is more straightforward in classifying individuals at high risk of using 
cigarettes + ATPs. This model identified fewer factors associated with cigarettes + ATP use and 
revealed partial interactions that are not easy to find in logistic regression, thus provided clearer 
direction for identification and treatment in clinical practice. In general, the CART methodology 
can be used to classify high risk or at need groups for identification for treatment protocols 




Table 2.1: Univariate Differences between Smokers who Use Cigarettes in Combination with 
Alternative Tobacco Product (Cigarettes + ATP) Compared to those who use Cigarettes Only 







Demographics    
Male 662 (27.9%) 332 (14.0%) < 0.001 
Age (±SD) 40.24 ± 11.64 45.85 ± 12.62 < 0.001 
Race 
  African American 
  Latino 










Education, % college graduate or higher 474 (19.9%) 364 (15.3%) < 0.001 
Income, % < $1800/month 480 (20.2%) 463 (19.5%) 0.725 
Tobacco Characteristics    
Smoking status (%) 
  Nondaily 
  Daily light (1-10 cpd) 










Menthol smoker 737 (31.0%) 623 (26.2%) 0.001 
Cigarettes per day, mean (±SD) 9.30 ± 8.70 10.14 ± 8.52 0.017 
Time to first cigarette, % within 30 minutes of 
waking 
720 (30.3%) 629 (26.5%) 0.024 
24 hour quit attempts in last 12 months, mean (±SD) 5.50 ± 9.53 5.94 ± 11.79 0.451 
Cost    
Price of cigs influenced them to smoke less, % yes 726 (30.6%) 644 (27.1%) 0.061 
Price of cigs influenced where they buy cigs, % yes 840 (35.4%) 826 (34.8%) 0.166 
Price of cigs influenced the brand they buy, % yes 590 (24.8%) 455 (19.1%) < 0.001 
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Buy versus borrow cigs, % buy all cigs they smoke 683 (28.7%) 824 (34.7%) < 0.001 
Harm Reduction    
Trying to cut down on cigs smoke, % yes 862 (36.3%) 818 (34.4%) 0.955 
Limit cpd to decrease health risk, % yes 596 (25.1%) 505 (21.3%) 0.012 
Limit smoking in last year to decrease health risks, % 
always or often 
360 (15.2%) 356 (15.0%) 0.494 
Psychosocial    
Depression score, mean (±SD)a 2.14 ± 1.83 1.80 ± 1.84 < 0.001 
Alcohol score, mean (±SD)
b
 4.64 ± 3.10 3.30 ± 2.98 < 0.001 
Discrimination score, mean (±SD)
c
 8.28 ± 6.72 5.85 ± 5.66 < 0.001 
a
 Scores range from 0-6 with scores of 3 or higher indicating possible depressive symptoms  
b 
Scores range from 0-12 with scores of >4 for men and >3 for women indicating possible alcohol misuse 
c 













Table 2.2: Univariate Differences between training sample and validation sample 
 Training 
(n = 1584) 
Validation 
(n = 792) 
P value 
Demographics    
Male 657 (27.7%) 337 (14.2%) 0.617 
Age (±SD) 42.94 ± 12.39 43.03 ± 12.5 0.880 
Race 
  African American 
  Latino 










Education, % college graduate or higher 550 (23.1%) 288 (12.1%) 0.430 
Income, % < $1800/month 614 (25.8%) 329 (13.8%) 0.192 
Tobacco Characteristics    
Smoking status (%) 
  Nondaily 
  Daily light (1-10 cpd) 










Menthol smoker 899 (37.8%) 461 (19.4%) 0.500 
Cigarettes per day, mean (±SD) 10.03 ± 9.03 9.06 ± 7.69 0.009 
Time to first cigarette, % within 30 minutes of 
waking 
900 (37.9%) 449 (18.9%) 0.953 
24 hour quit attempts in last 12 months, mean 
(±SD) 
5.54 ± 9.87 6.00 ± 11.93 0.454 
Cost    
Price of cigs influenced them to smoke less, % yes 920 (38.7%) 450 (18.9%) 0.557 
Price of cigs influenced where they buy cigs, % yes 1100 (46.3%) 566 (23.8%) 0.311 
Price of cigs influenced the brand they buy, % yes 685 (28.8%) 360 (15.2%) 0.306 




(n = 1584) 
Validation 
(n = 792) 
P value 
Harm Reduction    
Trying to cut down on cigs smoke, % yes 1119 (47.1%) 561 (23.6%) 0.924 
Limit cpd to decrease health risk, % yes 730 (30.7%) 371 (15.6%) 0.727 
Limit smoking in last year to decrease health risks, 
% always or often 
476 (20.0%) 240 (10.1%) 0.899 
Psychosocial    
Depression score, mean (±SD)
a
 1.99 ± 1.86 1.96 ± 1.82 0.683 
Alcohol score, mean (±SD)
b
 4.02 ± 3.16 3.93 ± 3.03 0.494 
Discrimination score, mean (±SD)
c
 7.03 ± 6.30 7.23 ± 6.44 0.460 
a
 Scores range from 0-6 with scores of 3 or higher indicating possible depressive symptoms  
b 
Scores range from 0-12 with scores of >4 for men and >3 for women indicating possible alcohol misuse 
c 








95% CL for 
OR P-value 
Intercept -0.2617 NA NA 0.3497 
Age -0.0265 0.974  (0.964, 0.983)  <.0001 
Male 0.9766 2.655  (2.118, 3.329)  <.0001 
Buy vs. Borrow -0.4832 0.617  (0.486, 0.783)  <.0001 
Alcohol 0.0986 1.104  (1.064, 1.145)  <.0001 
Price influenced the brand they buy 0.3579 1.430  (1.144, 1.788)  0.0017 
African American vs. white 0.4576 1.580  (1.208, 2.066)  0.0008 
Latino vs. white 0.4170 1.517  (1.155, 1.994)  0.0028 
Discrimination 0.0259 1.026  (1.007, 1.045)  0.0065 
Time to first cig less than 30 min 0.4100 1.507  (1.197, 1.897)  0.0005 
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This research was motivated by our goal to design an efficient clinical trial to compare two doses 
of docosahexaenoic acid supplementation for reducing the rate of earliest preterm births and/or 
preterm births in a fixed Bayesian design framework. Dichotomizing continuous gestational age 
data and analyzing the data using a classic binomial distribution will result in a loss of 
information and reduced power. A distributional approach is an improved strategy for 
dichotomizing continuous data while retaining statistical power from the continuous distribution. 
However, appropriate distributions that fit the data properly, particularly in the tails, must be 
chosen, especially when the data are skewed. A recent study proposed log transformation and use 
of a normal distribution for the transformed gestational age data. We propose a three-component 
normal mixture model and introduce separate treatment effects at different components of 
gestational age. We evaluate operating characteristics of clinical trial designs comparing this 
mixture model with a beta-binomial model and a normal model applied to the log transformed 
data through simulation. We also apply these three methods to data from two completed clinical 
trials from the USA and Australia. Finite mixture models are shown to have favorable properties 
in preterm births analysis but limited benefit for earliest preterm births analysis. Normal models 
on log transformed data have the largest bias and are not as efficient as finite mixture models. 
Therefore we recommend finite mixture model for preterm births study.  Either finite mixture 
model or beta-binomial model is acceptable for earliest preterm births study. 
 




In many circumstances, clinical researchers are interested in studying categorized 
outcomes using cutoff points despite continuous measurements being collected. It has been 
widely accepted that dichotomizing continuous data prior to analysis results in a loss of 
information and reduced power (Altman & Royston, 2006; Deyi, Kosinski, & Snapinn, 1998; 
Peacock et al., 2012).
 
 A distributional approach can be used to dichotomize continuous data 
while retaining the statistical power from the continuous distribution (Peacock et al., 2012). 
Peacock et al. (2012) described the use of the distributional method and showed the good 
performance of this parametric approach under standard normal distributional assumptions 
(Peacock et al., 2012).  Sauzet et al. (2015) further discussed the distributional approach when 
the outcome is skewed and proposed a skew-normal distributional method for dichotomization 
(Sauzet, Ofuya, & Peacock, 2015).
 
They used a logarithm transformation to normalize negatively 
skewed gestational age data and then applied the skew-normal distributional method under the 
Frequentist framework. They acknowledged that no satisfactory transformation is available for 
gestational age data (Sauzet et al., 2015).
 
Mixture models with different components might be a 
better choice for skewed outcomes such as gestational age, because they allow for greater 
flexibility in modeling heterogeneous populations (McLachlan & Peel, 2000),
 
which largely 
explains the skewness of gestational age data.  
Our research was motivated by our goal to design an efficient clinical trial to compare 
two doses of docosahexaenoic acid (DHA) supplementation for reducing the rate of earliest 
preterm births (ePTB, gestation age<34 weeks) and/or preterm births (PTB, gestational age<37 
weeks). Both endpoints have been evaluated in past studies (Makrides et al., 2010).
  
The United 
States currently has a PTB rate of 11.4% (House, 2014) and babies born preterm are at increased 
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risk of immediate life-threatening health problems, as well as long-term complications and 
developmental delays (Gajewski, Reese, Colombo, & Carlson, 2016).
 
Among preterm infants, 
those babies who are born the earliest (<34 weeks) are at greatest risk of complications. 
Although the overall PTB rates have decreased over time, the ePTB rates in the U.S. have 
decreased little since 1990 and the overall ePTB rates in the US for 2012 were 3.4% (Martin, 
Hamilton, Osterman, Curtin, & Mathers, 2013).
 
 These births impact overall infant mortality the 
most and result in much higher hospital costs than uncomplicated births (Russell et al., 2007).
 
 
Docosahexaenoic acid (DHA) supplementation potentially provides a high yield, low risk 
provocative strategy to reduce early preterm delivery (Gajewski et al., 2016).
 
We designed a 
Phase III clinical trial (randomized to low or high dose DHA, double-blind) to examine the 
efficacy of 1000 mg/day DHA supplementation to reduce the probability of earliest preterm 
births and/or preterm births compared to 200 mg/day, an amount recommended by the 
FAO/WHO for pregnant and lactating women and currently in many prenatal supplements. Our 
goal was to identify a powerful design that would provide an efficient estimate of the treatment 
effect. 
Gestational age (GA) data will be measured in completed weeks/days and collected in a 
continuous form. The two clinically important endpoints of interest are: ePTB (GA<34 weeks) 
and PTB (GA<37 weeks). The traditional analysis approach is to dichotomize the continuous 
gestational age data using these cutoff points and to compare the probabilities of binary 
outcomes, using a chi-square test for example. Distributional methods compare the proportions 
below the cutoff points in continuous distributions (Gajewski et al., 2016; Peacock et al., 2012).
 
 
Sauzet et al. (2015) proposed a skew-normal method and used normal distribution on the 
logarithmic transformed data (Sauzet et al., 2015).
 
We propose a three-component normal 
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mixture model and apply the distributional approach directly. The aim of this study is to compare 
these three statistical methods under a fixed Bayesian design framework for a very rare endpoint 
(ePTB) and a less rare endpoint (PTB).  
The remainder of this article is arranged as follows. In section 2, we describe three 
statistical models using the pre-dichotomizing and distributional methods separately. In section 
3, we provide the simulation details under a fixed Bayesian clinical trial design framework and 
compare these three statistical methods in several realistic outcome scenarios. In section 4, we 
apply these three methods to data from two completed clinical trials, one in the USA and one in 
Australia. The results from the real data analysis are examined and compared. In section 5, we 
discuss the observations from the simulations and real data analysis and further investigate the 
rationale of these observations. In section 6, we discuss the limitations of this study. In section 7, 
we draw conclusions from our analysis and give suggestions to future studies. 
3.2 Statistical models  
Let Yj = (Yj1,…, Yjnj) denote the continuous data of gestational age, where j denotes the 
treatment group assignment (j=c for participants in the control group and j=t for participants in 
the treatment group) and nj denotes the sample size in the jth treatment group in a two-armed 
randomized clinical trial design. Let pj denote the probability of ePTB or PTB in the jth 
treatment group. 
The first method considered involves dichotomizing the data prior to modeling. We 
propose a beta-binomial model to simplify a Bayesian inference of P(pc > pt|data), denoting 
the posterior probability that control has a higher ePTB/PTB rate than treatment. Because the 
endpoints considered are rare, using a uniform prior or a beta (1,1) prior might induce non-
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negligible bias. We therefore assume a very weak prior of pj as beta (0.01, 0.01). Furthermore, 
the posterior mode is close to a classical Frequentist approach (i.e., Maximum Likelihood 
Estimator). Let Xj = ∑ I(Yji < 34 𝑜𝑟 37), where I(x < 𝑦) = {
1, x < 𝑦
0, x ≥ y
nj
i=1
 and nj is the sample 
size in the jth treatment group (i=1,..., nj). The distribution of Xj is assumed to follow a binomial 
distribution: Xj|pj~binomial(nj, pj). The posterior distribution of pj|Xj~ beta (Xj + 0.01, nj −
Xj + 0.01  ).  
The second method considered is a distributional approach, where we will apply the 
transformation recommended by Sauzet et al. (2015) (Sauzet et al., 2015).
 
First we take a 
logarithmic transformation of (45-GA) to normalize the data because we expect GA in weeks to 





2). Since the logarithmic transformation is a continuous and monotonic 
transformation, this does not affect the proportion below a cut-point (Sauzet et al., 2015).
 
The 
proportions of GA below 34 and 37 are translated into the proportions greater than log(45-34) 
=2.3979 and log(45-37) =2.0794 in the normal distribution N(μj, σj
2).  We use non-informative 
conjugate priors for the parameters in the normal distribution: N(0, 1002) for μj and Gamma 
(0.001, 0.001) for 
1
σj




2.3979 or 2.0794 
 dy, where ɸ(y|μj, σj











∑ (Zji − Zj̅)
2nj
i=1












The third method considered is another distributional approach using the finite normal 
mixture model. Peacock et al. (2012) showed the good performance of the parametric approach 
under traditional normal distributions (Peacock et al., 2012).
 
We extend this approach here and 
propose a finite mixture normal model to allow for population heterogeneity. In this method, we 
apply a three-component normal mixture model derived from the North Carolina Detailed Birth 
Record (NCDBR) database with 336,129 observations in the final analysis: a three-component 
mixture of N(39.59, 0.96), N(38.26, 2.48), and N(33.29, 13.23) (Schwartz, Gelfand, & Miranda, 
2010).  The 95% CIs for the parameter estimates in this model show these estimates are reliable 
in this registry data. The first component has a mean of 39.59 (39.58, 39.61), and variance of 
0.96 (0.95, 0.97). The second component has a mean of 38.26 (38.20, 38.32) and variance of 
2.48 (2.42, 2.54). The third component has a mean of 33.29 (33.07, 33.51) and variance of 13.23 
(12.78, 13.67) (Schwartz et al., 2010).
 
Although we used fixed parameter estimates from a U.S. 
registry data, this model has unprecedented advantages in gestational age data analysis or clinical 
trial design, even for a different population. Firstly, the parameter estimates are derived from a 
huge registry data thus is representative and has generalizablility. Secondly, a three-component 
mixture normal model has its own flexibility to model similar but not exactly the same 
gestational age data from a different population by allowing various component weights. Thirdly, 
the three components are realistic and interpretable. The three components represent low, 
medium, and high-risk groups for PTB separately. We assume a unity prior for ∆j (j=c,t), the 
mixture weights in the jth treatment group, and the three-component normal mixture model can 
be written as: f(Yji|∆j)=∆1jɸ(Yji|39.59, 0.96) + ∆2jɸ(Yji|38.26, 2.48)+∆3jɸ(Yji|33.29, 13.23), 
where ɸ (y|μ, σ2) denotes the density of y in a normal distribution with mean μ and variance σ2, 
and  ∆1j, ∆2j, and ∆3j denote the mixture weights in the jth treatment group, with ∆1j +  ∆2j +
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∆3j= 1. In this method, the posterior probability of ePTB or PTB (pj|Yj) is calculated as: 
pj|Yj = ∫ f(y|∆j)
34 or 37
−∞
 dy. A more general approach would be to let each component’s mean 
and variance be freely modeled. However, we found our approach was flexible and appropriate 
for our focus on the lower tail. Furthermore, fixing the components avoids some of the 
identifiability issues found in general mixture models (McLachlan & Peel, 2000).
  
3.3 Fixed Bayesian clinical trial design and simulation study  
A previous Phase III trial comparing 600 mg DHA per day and placebo, Kansas 
University DHA Outcome Study [KUDOS], found an 85% reduction in ePTB with DHA 
supplementation (Carlson et al., 2013). Another Australian trial, DHA to Optimize Mother Infant 
Outcome [DOMInO] trial, which compared 800 mg DHA per day and placebo, found a 50% 
reduction in ePTB with DHA supplementation (Makrides et al., 2010). In both trials, ePTB was a 
secondary outcome (Carlson et al., 2013; Makrides et al., 2010). The primary aim of the current 
proposed Phase III randomized, double-blind trial is to test the hypothesis that ePTB and/or PTB 
is reduced by 1000 mg of DHA per day compared to 200 mg DHA per day. We performed a 
simulation study based on realistic response scenarios to investigate the operating characteristics 
of this fixed Bayesian clinical trial design. 
3.3.1 Simulation methods  
We simulated gestational age data using different true values of mixture weights (∆0) 
with resulting probabilities of ePTB or PTB close to probability scenarios we observed from our 
clinical trials (Carlson et al., 2013). In the beta-binomial model, we used simulation to generate 
the posterior distribution of  pj|Xj~ beta (Xj + 0.01, n − Xj + 0.01  ) for both treatment and 
control groups and calculated the probability of pc|Xc > pt|Xt. In the finite mixture model, we 
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used Markov Chain Monte Carlo (MCMC) to generate posterior distributions of ∆j and the 
posterior probability pj|Yj was calculated as: pj|Yj = ∫ f(y|∆j)
34 or 37
−∞
 dy. In the logarithmic 
transformation method, we used Gibbs sampling to generate posterior distributions of 
μjp and σjp
2 . The posterior probability pj|Zj was calculated as ∫ ɸ(y|μjp, σjp
2 )
∞
2.3979 or 2.0794 
 dy. If 
Pr(pc > pt|data) > 𝛿, we counted this as a trial success. The posterior mean of pj|data, 
pĵ = E(pj|data), was saved for each simulation in each of the three models. In all models, the 
expected estimated probability of ePTB or PTB, E(pĵ) was calculated as the average of pĵ across 





  for each treatment 
group, where S was the number of simulations. The MSE of E(pĵ) was calculated as bias
2 +
 sample variance = (E(pĵ)  − Pj,0)
2 + Vj, with Pj,0 denoting the true probability of ePTB or PTB 
in the jth treatment group.  
To mimic situations for ePTB in future trials, we simulated 5 scenarios with varying 
treatment effects: no effect (3 vs. 3%, difference=0), very small (3 vs. 2%, difference=1%), small 
(3 vs. 1%, difference=2%), medium (3 vs. 0.5%, difference=2.5%) and large (4 vs. 1%, 
difference=3%) based on our previous clinical trial results (Carlson et al., 2013). To mimic 
situations for PTB in future trials, we simulated another 5 scenarios: no treatment effect (8 vs. 
8%, difference=0), very small (8 vs. 7%, difference=1%), small (8 vs. 6%, difference=2%), 
medium (8 vs. 5%, difference=3%) and large (8 vs. 4%, difference=4%) based on results from 
our previous clinical trial (Carlson et al., 2013).
 
In the null scenarios where the treatment effect 
was 0, we identified the δ values which made the average success rate across simulations 
approximately equal to 0.05, P(Pr(pc > pt|data) > 𝛿)  ≈ 0.05. δ values can vary in different 
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statistical methods. This ensured the type I error rate was about 5%. In other scenarios, 
P(Pr(pc > pt|data) > 𝛿) was used to calculate the power of the tests. 
We compared the simulated trial operating characteristics, (bias, power and MSE) across 
the three models for both ePTB and PTB. These were based upon 1000 simulations and 600 
subjects in each group because our designed trial has a sample size around 1200.  The δ value 
was 0.95 for both ePTB and PTB simulations, in the beta-binomial model and the finite mixture 
model. In the logarithmic transformation model, δ was 0.999 for ePTB simulations and 0.997 for 
PTB simulations. All methods were implemented in R 3.1.1 and Openbugs. 
3.3.2 Simulation results  
In the simulation study of probability of ePTB (<34 weeks), the beta-binomial model had 
lower bias compared to the finite mixture model and the logarithmic transformation model in all 
scenarios. The MSE in the finite mixture model was consistently lower than in the beta-binomial 
model and logarithmic transformation model in the control group and slightly higher than in the 
beta-binomial model in the last three scenarios in the treatment group (Table 3.1).  Figure 3.1 
shows the comparisons of bias, variance, MSE and power across the three models. In the null 
scenario, the type I error rate was 0.048 in the beta-binomial model, 0.054 in the finite mixture 
normal model, and 0.053 in the logarithmic transformation model (Table 3.1). The power for the 
finite mixture model was slightly higher than the beta-binomial model in other scenarios, but the 
difference was small (Figure 3.1). The logarithmic transformation model had the largest bias and 




Figure 3.1: Simulated Trial Operating Characteristics for Probability of ePTB (GA<34 weeks) 
 
In the simulation study of probability of PTB (<37 weeks), the beta-binomial model 
continued to have lower bias compared to the finite mixture normal model and the logarithmic 
transformation model. The difference in MSE between the finite normal mixture model and the 
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beta-binomial model was larger than that in the ePTB simulations (Table 3.1 and Table 3.2). The 
logarithmic transformation model again had the largest bias and largest MSE (Table 3.2).  In the 
null treatment effect scenario, the type I error rate was 0.054 in the beta-binomial model, 0.05 in 
the finite mixture normal model, and 0.051 in the logarithmic transformation model (Table 3.2). 
The power for the finite mixture model was higher than the beta-binomial model in other 
scenarios, with differences as large as 7.5% when the true effect was likely (8 vs. 5%)  (Table 
3.2). Figure 3.2 shows the comparisons of bias, variance, MSE and power across the three 
models. 
These simulation results demonstrated that although the bias from the finite mixture 
method was slightly larger than that from the pre-dichotomizing method, the parameter estimates 
from the finite mixture method had desirable properties such as lower MSE and lower variance. 
In ePTB simulation, the finite mixture model did not appear to be more desirable than the beta-
binomial model. However, the advantages of the finite mixture model became apparent in PTB 
analysis. The logarithmic transformation method has the largest bias and highest MSE. In a 
word, the logarithmic transformation model appeared to be inferior to the finite mixture model. 
3.4 Application to real data  
To illustrate the use of the three models in real data, we reanalyzed the gestational age 








Figure 3.2: Simulated Trial Operating Characteristics for Probability of PTB (GA<37 weeks) 
 
3.4.1 DOMInO trial  
The DOMInO trial was a double-blind, multicenter, randomized controlled trial 
conducted in five Australian maternity hospitals. The trial included 2399 women who were less 
than 21 weeks' gestation with singleton pregnancies and who were recruited between October 31, 
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2005, and January 11, 2008 (Makrides et al., 2010).
 
This study compared fish oil capsules 
(providing 800 mg/d of DHA) or matched vegetable oil capsules without DHA. Gestational age 
data were available for 2367 (1183 in control and 1184 in treatment) participants in this study. 
We looked at the posterior summary statistics of the posterior component probabilities in 
the control and treatment groups from the finite mixture model (Table 3.3). Compared to the 
control group, the posterior probability of the first component (low risk of PTB) increased from 
0.783 to 0.813 and the posterior probability of the third component (high risk of PTB) decreased 
from 0.04 to 0.022. The posterior probability of the second component decreased a little from 
0.177 to 0.165. Convergence diagnostics were checked to ensure the convergence of posterior 
samples. 
In Table 3.4, we show the calculated and estimated probability of ePTB and PTB and the 
standard deviation of the estimated probabilities. In this analysis, we found the benefits of the 
finite mixture model were not clear in ePTB but the standard deviation was slightly smaller in 
the finite mixture model in PTB analysis. The estimated proportions for the log transformation 
model are quite different to the raw data (Table 3.4). 
3.4.2 KUDOS trial  
KUDOS was a Phase III, randomized, double-blind, placebo-controlled clinical trial 
involving 299 women (Carlson et al., 2013). This study compared participants in the placebo 
group (n1 = 145) and participants who received 600 mg/day DHA (n2 = 154) in the second and 
third trimester during pregnancy from 2001 to 2006 in the University of Kansas Hospital 




The posterior summary statistics of the mixture weights were summarized in Table 5. 
Compared to the DOMInO trial, the difference in the three component probabilities between 
treatment and control groups was much larger (Table 3.3 and Table 3.5). The mixture weight of 
the third component (high risk of PTB) decreased dramatically from 0.089 in the control group to 
0.029 in the intervention group. Convergence diagnostics were checked to ensure the 
convergence of posterior samples. 
In Table 3.6, we show the calculated and estimated probability of ePTB and PTB and the 
standard deviation of the estimated probabilities. Again in this analysis, we found the advantages 
of the finite mixture model compared to beta-binomial model were not very clear for ePTB but 
the standard deviation was smaller in the finite mixture model for PTB. Both the DOMInO and 
KUDOS data were consistent with the simulation studies and show that the benefits of the finite 
mixture model are evident for PTB but questionable for ePTB. The logarithmic transformation 
model produced quite different results compared to the other two models, which may be due to 
the bias in this method observed in the simulation study. 
3.5 Discussion  
We aimed to investigate the properties of pre-dichotomizing and distributional 
approaches using a three-component normal mixture model and a logarithmic transformation 
model. The three-component normal mixture model has been demonstrated to be identifiable and 
superior to two-component mixture models while avoiding the poor mixing in models with four 
or more components (Schwartz et al., 2010).
 
The Bayesian framework provides us with a 
convenient tool to compare distributional approaches and the pre-dichotomizing method.  
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In the simulation study, we used a weak beta prior for the beta-binomial model to ensure 
the bias was negligible and the estimates were close to the Frequentist approach. As a result, the 
bias from the finite mixture model was greater than that from the beta-binomial model. However, 
the finite mixture model had lower variance in all scenarios. In the ePTB analysis where the 
endpoint was very rare, the power of the finite mixture model was only slightly higher than the 
beta-binomial model and the benefits of the finite mixture model were relatively small. The 
benefits of the finite mixture model were more apparent in the PTB analysis where the endpoint 
was less rare. In this case, the variance and hence the MSE were much lower and the power was 
higher in the finite mixture model compared with the other methods. The logarithmic 
transformation model had the largest bias and MSE. 
In real data analysis, both DOMInO and KUDOS trial data demonstrated the advantages 
of the finite mixture model in PTB analysis. The finite mixture model had lower standard 
deviation compared to the beta-binomial model for PTB in both datasets. The logarithmic 
transformation model produced quite different results in both analyses. These findings confirmed 




Further investigating the three-component mixture model facilitates understanding of our 
observations in the simulation study and real data analysis. The three mixture components are: 
N(39.59, 0.96), N(38.26, 2.48), and N(33.29, 13.23). The mixture weights are about 70-80% for 
the first component, 10-20% for the second component, and less than 10% for the third 
component. The three components have different means and standard deviations 
(heteroscedastic). Therefore it is not straightforward to describe the exhibition of the mixture 
distribution. However, we can still speculate the mixture exhibition from the three mixture 
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components and the mixture weights. The first two components have close means and different 
standard deviations. Distribution mixing these two will display high kurtosis with a sharper peak 
and heavier tails than a single distribution (Gridgman, 1970).
 
The third component is sufficiently 
separated from the first two components. The difference in the means between the second and 
third components is greater than two times the standard deviation of the second component. 
Mixing of these two could form a bimodal distribution (Schilling, Watkins, & Watkins, 2002).
 
 
Since the mixture weights of the first two components are dominant and the standard deviation 
of the third component is large, the exhibition could have a long left tail with a small peak on the 
tail.  
Based on the exploration of the finite mixture model, we can obtain an intuitive 
explanation of our observations. In the ePTB analysis we used GA<34 as a cutoff. Given the 
exhibition of the mixture model, the area below 34 was mainly captured by the third component 
of the distribution. In the PTB analysis we used GA<37 as a cutoff and the area below 37 was 
comprised of the second and the third components, while the influence of the first component 
was trivial. Therefore in the ePTB analysis, the finite mixture model did not appear to be much 
better than the beta-binomial model in terms of power because most of the information we 
needed to make inference on the probability of ePTB was captured by one mode in a bimodal 
exhibition. In the PTB analysis, the information to make inference on the probability of PTB was 
captured by two components and the finite mixture model captured the information from the 
trend of the two components and retained the power from the continuous distribution. Gestation 
age analysis is a single example in real life where we care about dichotomized outcomes while 
continuous data are collected. This study showed the cutoff value and the exhibition of the 
distribution were important to understand the mechanism of gaining power from a continuous 
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distribution.  This conclusion can be generalized to other studies in which the outcome is 
dichotomized while data are collected in a continuous form. 
3.6 Limitations  
There are a few assumptions we have made to pursue this study. Firstly, we used the 
parameter estimates of the normal components from the North Carolina Detailed Birth Record 
(NCDBR) database and applied them to different populations. We assumed these component 
parameters were valid in different populations and they appeared to be fine in this study as the 
estimated probabilities are quite close to the true data. Although the finite mixture model has 
certain flexibility to allow component weights to vary, the parameter estimates or even the 
formation of the mixture model could change in other populations if the population is extremely 
different. Secondly, we assumed there was no measurement error in the gestational age data. 
Gestational age data were obtained from medical records but we do not have a technique to test 
the measurement error in the current study. If the measurement error was large, it could blur the 
boundary of ePTB and PTB.  
3.7 Conclusion  
In studies where endpoints are collected as continuous variables but clinicians are 
interested in studying dichotomized outcomes, a pre-dichotomizing or distributional approach 
could be used for analysis. In general, a distributional approach that fits the data well retains 
information and power from the continuous distribution, while a dichotomizing method is close 
to the traditional Frequentist approach and may result in less bias. The benefits of a distributional 
method depend on model fit, cutoff values, and the exhibition of the continuous distribution. 
Meticulous investigation of the distributions is necessary, especially in rare endpoint analysis 
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where retaining statistical power is more important. In our clinical trial designs for gestational 
age data, we recommend the finite mixture normal model if the endpoint is PTB (<37 weeks) 
since this is a more powerful design and think either finite mixture normal model or beta-
binomial model is acceptable if the endpoint is ePTB (<34 weeks) since the power from these 




Table 3.1: Simulated Trial Operating Characteristics for Probability of ePTB (GA<34 weeks) 
 
Scenarios  Bias MSE×105 Power 
 Method Control Tx Control Tx  
No 
difference  
(3 vs. 3%) 
B-B .00009 .00006 4.62 4.78 .048 
F-M .00144 .00119 4.02 4.17 .054 
L-T .01983 .01954 58.56 59.21 .053 
Very Small 
(3 vs. 2%) 
B-B .00037 .00005 4.53 3.39 .275 
F-M .00099 .00123 4.08 3.13 .286 
L-T .02051 .01493 53.46 28.14 .164 
Small 
(3 vs. 1%) 
B-B .00034 .00028 5.03 1.69 .845 
F-M .00160 .00171 4.63 1.82 .857 
L-T .02051 .00713 53.46 7.19 .58 
Medium 
(3 vs. 0.5%) 
B-B .00043 .00004 4.69 0.89 .983 
F-M .00156 .00160 4.20 1.00 .985 
L-T .01983 .00347 58.58 2.51 .794 
Large 
(4 vs. 1%) 
B-B .00010 .00010 6.57 1.51 .984 
F-M .00120 .00143 5.47 1.55 .989 
L-T .02554 .00667 89.75 10.72 .863 
Power: average success rate across simulations, P(Pr(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿), 𝛿 = 0.95 for Beta-
binomial and finite mixture model, 𝛿 = 0.999 for logarithmic transformation model 
B-B: Beta-Binomial model 
F-M: Finite Mixture model 




Table 3.2: Simulated Trial Operating Characteristics for Probability of PTB (GA<37 weeks) 
 
Scenarios  Bias MSE×105 Power 
 Method Control Tx Control Tx  
No 
difference  
(8 vs. 8%) 
B-B .00056 .00003 12.3 11.6 .054 
F-M .00235 .00224 10.3 10.1 .05 
L-T .03265 .03286 175 178 .051 
Very Small 
(8 vs. 7%) 
B-B .00002 .00016 12.6 11.4 .164 
F-M .00184 .00239 10.4 9.59 .163 
L-T .03266 .02859 175 151 .129 
Small 
(8 vs. 6%) 
B-B .00070 .00024 12.1 9.05 .378 
F-M .00149 .00218 9.90 7.47 .418 
L-T .03266 .02134 175 98 .343 
Medium 
(8 vs. 5%) 
B-B .00051 .00006 12.2 7.86 .693 
F-M .00224 .00225 10.8 6.33 .768 
L-T .03266 .01439 175 56 .687 
Large 
(8 vs. 4%) 
B-B .00025 .00008 12.9 6.64 .908 
F-M .00224 .00246 11.5 4.98 .952 
L-T .03223 .00789 157 19 .94 
Power: average success rate across simulations, P(Pr(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿), 𝛿 = 0.95 for Beta-
binomial and finite mixture model, 𝛿 = 0.997 for logarithmic transformation model 
B-B: Beta-Binomial model 
F-M: Finite Mixture model 




Table 3.3: Posterior statistics for mixture weights in finite mixture model in DOMInO trial  
(10000 simulations) 
 Control  Treatment 
 mean std  mean std 
∆1 .783 .022  .813 .021 
∆2 .177 .023  .165 .021 
∆3 .040 .007  .022 .006 
∆1: posterior probability of component 1, N(39.59, 0.96) 
∆2: posterior probability of component 2, N(38.26, 2.48) 




Table 3.4: Domino Data analysis: calculated and estimated probability and standard deviation 
(10000 simulations) 
 Outcome Data Estimated Prob. And SD 
   Pc0 Pt0 Pc Pt SDc SDt 
B-B <34 wks .023 .011 .023 .011 .004 .003 
 <37 wks .072 .055 .072 .055 .008 .007 
F-M <34 wks .023 .011 .024 .013 .004 .003 
 <37 wks .072 .055 .075 .057 .007 .006 
L-T <34 wks .023 .011 .009 .004 .001 .001 
 <37 wks .072 .055 .099 .068 .007 .007 
B-B: Beta-Binomial model 
F-M: Finite Mixture model 
L-T: Logarithmic Transformation model 
Outcome: probability of GA less than a certain amount of time 
Pc0: the calculated probability in the data in control group 
Pt0: the calculated probability in the data in treatment group 
Pc:  the estimated probability in the control group 
Pt: the estimated probability in the treatment group 
SDc: standard deviation in the control group 












Table 3.5: Posterior statistics for mixture weights in finite mixture model in KUDOS trial  
(10000 simulations) 
 Control  Treatment 
 mean std  mean std 
∆1 .838 .048  .775 .060 
∆2 .073 .048  .196 .063 
∆3 .089 .027  .029 .018 
∆1: posterior probability of component 1, N(39.59, 0.96) 
∆2: posterior probability of component 2, N(38.26, 2.48) 




Table 3.6: KUDOS Data analysis: calculated and estimated probability and standard deviation 
(10000 simulations) 
 Outcome Data Beta-Binomial Model 
   Pc0 Pt0 Pc Pt SDc SDt 
B-B <34 wks .048 .007 .048 .007 .018 .007 
 <37 wks .09 .065 .09 .065 .024 .02 
F-M <34 wks .048 .007 .052 .018 .016 .011 
 <37 wks .09 .065 .094 .069 .022 .017 
L-T <34 wks .048 .007 .016 .004 .006 .002 
 <37 wks .09 .065 .136 .069 .023 .016 
B-B: Beta-Binomial model 
F-M: Finite Mixture model 
L-T: Logarithmic Transformation model 
Outcome: probability of GA less than a certain amount of time 
Pc0: the calculated probability in the data in control group 
Pt0: the calculated probability in the data in treatment group 
Pc:  the estimated probability in the control group 
Pt: the estimated probability in the treatment group 
SDc: standard deviation in the control group 
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Background   Personalized medicine aims to match patient subpopulation to the most beneficial 
treatment. The purpose of this study is to design a prospective clinical trial in which we hope to 
achieve the highest level of confirmation in identifying and making treatment recommendations 
for subgroups. This study was motivated by our goal to identify subgroups in a DHA 
(docosahexaenoic acid) supplementation trial to reduce preterm birth (gestational age<37 weeks) 
rate.  
Methods  We used four subgroups with 250 subjects in each group as an example and ordered 
the subgroups’ risk levels in the control arm (placebo or current standard of care). The 
experimental arm had four groups of same sample sizes with changed risks. We simulated 
operating characteristics to ensure that overall Type I error rate was close to 0.05 in designs with 
four different models: naïve logistic, independent, hierarchical, and dynamic linear models.  We 
obtained an informative prior distribution through a meta-analysis that included nine clinical trial 
studies across the world. We then carried out simulations and sensitivity analysis to examine the 
subgroup power of the four models and compared the results to a chi-square test. 
Results  We examined a large overall effect scenario and a small overall effect scenario, and 
within each scenario, three situations in which the resulting rates in experimental arm were 
linear, flat, or nonlinear, to mimic situations that subgroups benefited differently. The logistic 
model was excluded because it was not flexible and induced large Type I error rate in certain 
subgroup analysis. In the large overall effect setting, dynamic linear model increased the power 
of the most affected group by 2.9% - 3.3% compared to hierarchical model, 4.3% - 8.6 % 
compared to independent model, and 7% - 10% compared to chi-square test. Dynamic linear 
model outperformed the other models in most other subgroup analysis. In the small overall effect 
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setting, dynamic linear model increased the power of the most affected group by 2% compared to 
hierarchical model, 1.6 % compared to independent model, and 14.2% compared to chi-square 
test when the resulting rates are linear. It increased the power of the most affected group by 14% 
compared to hierarchical model, 13.2 % compared to independent model, and 16.1% compared 
to chi-square test when the resulting rates are flat. It was outperformed by hierarchical model or 
chi-square test when the resulting rates are non-linear. Dynamic linear model remained robust 
and powerful in other subgroup analysis. 
Conclusions  Compared to independent and hierarchical models, dynamic linear model tends to 
be relatively robust and powerful when the control arm has ordinal risk groups.  
 




4.1 Introduction  
An important trend in treatment paradigm is personalized medicine, which is aimed to match 
patients to the most beneficial treatments. Patient populations are heterogeneous even in the 
same study. Characteristics vary between individuals, such as demographics, life style, genetic 
variants, etc. These varied characteristics can potentially modify the treatment effects on 
different individuals or subsets of patient populations. It is important to distinguish the subgroups 
that benefit the most and subgroups that don’t benefit or might even unnecessarily be exposed to 




Our research was motivated by our goal to 
design a clinical trial to identify subgroups in a trial to supplement pregnant women with 
docosahexaenoic acid (DHA) to reduce the rate of preterm births (PTB, gestational age<37 
weeks). This is the first step in an enrichment design where a certain subgroup will be identified 
and the succeeding steps will distinguish the treatment effect within the selected (enriched) 
subpopulation 
 
(Fedorov & Liu, 2007).  
Berry et al. (2013) discussed three clinical trial designs assuming four groups of patients 
under an adaptive framework: Simon’s Optimal Two-Stage design, a Bayesian independent 
design, and a Bayesian hierarchical design (Berry, Broglio, Groshen, & Berry, 2013). They 
showed that the hierarchical model could provide additional power and reduction in sample size 
compared to other two methods but acknowledged that hierarchical modeling could make finding 
a single effective group more difficult, if there was only one (Berry et al., 2013). We followed 
their four-group design in this study. The four-group design is an example for illustration and can 
be generalized to different settings. The hierarchical model does not require the entities to be 
related  (Berry et al., 2013). In practice it is common to classify subjects into different risk levels 
of subpopulations. We classified the four groups according to their risk levels assuming they are 
57 
 
receiving placebo or standard of care (control arm). Our study extended Berry et al. (2013) and 
aimed to identify a more efficient design from a prospective perspective to achieve the highest 
level of confirmation in identifying and making recommendations for subgroups  (Ruberg & 
Shen, 2015), given the fact that the risk groups can be ordered in the control arm.  
Two major considerations on subgroup analysis in clinical trial designs are: preserving Type 
I error and improving power (Simon & Simon, 2013). Testing each hypothesis in a multi-group 
study inflates the overall Type I error rate. Multiplicity adjustment is required to preserve the 
overall Type I error rate (Alosh et al., 2015). We calibrated the operating characteristics in 
simulations to ensure the overall Type I error rate was close to 0.05 (one-sided) in all designs 
that used different statistical models. Approaches to improve statistical power in subgroup 
analysis include: using available information from previous studies
 
(Alosh et al., 2015) and 
borrowing information across subgroups (Berry et al., 2013). We did a meta-analysis that 
contained data from nine DHA supplementation trials across the world to obtain informative 
priors. Then informative priors were applied to three different models: independent model, 
hierarchical model, and dynamic linear model. A naïve logistic model was studied but 
uninformative priors were used because no prior information was available for the parameters in 
this model. All methods were compared to the chi-square test to see the benefit of each model in 
the trial design. 
The remainder of this article is arranged as follows. In section 2, we obtained informative 
prior distributions through meta-analysis based upon nine previous clinical trials across the 
world. In section 3, we described the four statistical models in trial designs. In section 4, we 
explained the computation methods and software we used. In section 5, we discussed the results 
from the simulations. In section 6, we performed a sensitivity analysis and discussed potential 
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concerns. In section 7, we draw conclusions from our analysis and give suggestions to future 
studies. 
4.2 Prior Distributions  
In subgroup analysis, a prior distribution is assumed for subgroup-specific treatment effect 
(Alosh et al., 2015). There are advantages and disadvantages of using both non-informative and 
informative priors. When historical data for the control arm are consistent with current study 
data, using informative priors constructed from previous complete trials can improve testing 
power and generate robust results (Chen et al., 2015). We performed a meta-analysis based on 
nine completed DHA supplementation trials that contain preterm birth data across the world. 
Five of them were included in a review study conducted by the Cochrane Collaboration: 
Denmark 1992, England 1995, Europe 2000, Netherlands 1994, and USA 2003 (Makrides, 
Duley, & Olsen, 2006). Besides these we included four other trials: KUDOS (Kansas University 
Hospital) 2013 (Carlson et al., 2013), DOMInO (Australia) 2010  (Makrides et al., 2010), 
Mexico 2015 (Ramakrishnan et al., 2015), and NICHD (USA) 2010 (Harper et al., 2010). The 
data from these studies are summarized in Table 4.1. 
We used a hierarchical model with relatively weak priors to obtain future prior distributions. 
Let 𝑃𝑖𝑗 denote proportion of preterm birth in the 𝑖
𝑡ℎ study (i=1,…9) and 𝑗𝑡ℎ arm (j=0,1; 
0=control, 1= experimental). We modeled 𝜃𝑖𝑗 = log (
𝑃𝑖𝑗
1−𝑃𝑖𝑗
) ~ 𝑁(𝜇, 𝜏), where 𝜏 is the precision 
(1/variance), with relatively weak hyper priors: 𝜇~ 𝑁(−2, 0.5) and 𝜏~𝐺𝑎𝑚𝑚𝑎 (1, 1). Future 
priors for 𝜇 and 𝜏 were derived from the averaged methods of moment estimators in the posterior 
distributions from the experimental arm and control arm. The posterior mean for 𝜇 is -1.872 in 
the control arm and -1.944 in the experimental arm. The posterior mean for 𝜏 is 1.273 in the 
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control arm and 1.287 in the experimental arm. The standard deviation for 𝜏 is 0.5874 in the 




= −1.91.  The estimator for 𝜏 is calculated as 
1.273+1.287
2
= 1.28. The 










= 0.3534. In this way we obtained informative priors 
𝜇~𝑁(−1.91, 1.28) and 𝜏~ 𝐺𝑎𝑚𝑚𝑎(4.6361, 3.622). Based on these prior distributions, the 
median of the proportion is 12.8%. This estimation is reasonable and consistent, as the current 
preterm birth rate in the US is about 11.4%  (House, 2014). We applied these informative priors 
to simulations in the following trial designs. 
4.3 Statistical Models in Trial Designs  
We used four risk groups for illustration but the conclusion applies more generally.  We 
assumed equal sample size of 250 subjects in each subgroup in both control and experimental 
arm. Two scenario settings were considered. The first scenario represents large overall treatment 
effect. The overall PTB rates are 8% vs. 4% in control and experimental arm respectively. The 
second scenario represents small overall treatment effect. The overall PTB rates are 8% vs. 6% 
in control and experimental arm respectively. These percentages are consistent with the results 
from our previous DHA supplementation trial (Carlson et al., 2013). The control arm in both 
scenarios has the same structure with ordinal PTB rates in the four subgroups (4%, 6%, 10%, 
and, 12% respectively). Within each scenario, we designed three different situations where the 
resulting rates in the experimental arm are linear, flat, or nonlinear (Table 4.2). We compared 
four trial designs and a chi-square test with Bonferroni correction for Type I error rate.  
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4.3.1 Naïve logistic Model  
This design was originated from a naïve assumption that the PTB proportions can be 




) =  𝛽0 + 𝛽1 × 𝑗, 𝑖 = 0,1; 𝑗 = 1,2,3,4  
This model assumed the difference between one risk level and the next level is a constant at 
the logit scale. Since no previous research studied the relationship between the preterm birth 





4.3.2 Independent Model  
We followed Berry et al. (2013) and examined an independent model (Berry et al., 2013). In 
this design, we presented a Bayesian model with no borrowing from subgroups but we did 
borrow information from previous studies by applying the informative priors obtained through 
meta-analysis. We modeled the rate in each subgroup within each arm separately through: 
𝜃𝑖𝑗 = log (
𝑃𝑖𝑗
1 − 𝑃𝑖𝑗
) , 𝑖 = 0,1; 𝑗 = 1,2,3,4 
The prior distribution for 𝜃𝑖𝑗 is: 
𝜃𝑖𝑗~ 𝑁(−1.91, 1.28) 
This informative prior results in mean proportion close to 12.8% but it can generate a 
proportion ranges from about 0.8% to 60%.  
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4.3.3 Hierarchical Model  
This is another design that was examined in Berry et al. (2013) (Berry et al., 2013). This 
design integrates the heterogeneous information from each subgroup. The hierarchical model 
assumes the four groups are exchangeable and allowed borrowing information across the four 
groups. In this design we model 𝜃𝑖𝑗 with a normal distribution with unknown mean and precision 
𝜃𝑖𝑗~𝑁(𝜇𝑖 , 𝜏𝑖) 𝑖 = 0,1; 𝑗 = 1,2,3,4 
By introducing a hierarchy to model the unknown mean and precision, the design borrows 
information from previous studies and the current data across the four groups. 
𝜇𝑖~𝑁(−1.91, 1.28) 
𝜏𝑖~ 𝐺𝑎𝑚𝑚𝑎 (4.6361, 3.622) 
Bigger 𝜏 indicates more pooling and information borrowing across the groups and smaller 𝜏 
represents less pooling, or more heterogeneity across the groups. Our priors from meta-analysis 
show significant heterogeneity from the data in previously conducted clinical trials and we think 
it is reasonable to remain the heterogeneity in our simulation analysis to apply to a general 
population.  
4.3.4 Dynamic Linear Model  
Dynamic linear model is another model that has an intrinsic hierarchical structure. Unlike 
the hierarchical model that we discussed in the previous section, the dynamic linear model does 
not assume exchangeability of the four groups and borrows more information from adjacent 
groups. The motivation is that this model might be more efficient since the four groups have 
ordinal risk levels at baseline so the correlation between adjacent groups might be larger. 
Therefore the dynamic linear model might capture the locally smooth trend better. In this design, 
the first group has a prior we obtained through meta-analysis, and the other groups have a 
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hierarchical structure, with a common precision and a mean related to the neighborhood means 
(Leininger, Reese, FEllingham, & Grimshaw, 2010).  
For the first group, we have: 
𝜃𝑖1~𝑁(−1.91, 1.28); 𝑖 = 0,1 
For the other groups, 
𝜃𝑖𝑗~𝑁(𝜃𝑖,𝑗−1, 𝜏𝑖);  𝑖 = 0,1;  𝑗 = 2,3,4 
and  
𝜏𝑖~ 𝐺𝑎𝑚𝑚𝑎 (4.6361, 3.622). 
The second group directly borrows information from the first and the third. The third group 
directly borrows information from the second and the fourth. The first group directly borrows 
information from previous studies and the second group. However, since the borrowing process 
is dynamic, the groups not adjacent directly impact each other through an indirect borrowing 
mechanism. This structure allows groups to borrow more information from adjacent groups 
which locally smoothes the trend. 
4.4 Computation  
In each scenario, 1000 simulated trials were used. We assumed the experimental and control 
arms each had four subgroups and each subgroup had 250 patients. The PTB rates in the four 
groups under the control arm were ordered and represented the risk levels assuming subjects 
were receiving placebo or standard of care. The PTB rates in the four groups under the 
experimental arm represented the risk levels after treatment, e.g., DHA supplementation. Data 
were simulated from binomial distribution based upon the proportions in each scenario using R 
3.2.2. All Bayesian computations were performed using OpenBUGS from within R 3.2.2. 
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OpenBUGS is powerful and flexible because it includes a system that determines an appropriate 
MCMC for analyzing a specified model without requiring a closed analytic form. 
4.5 Results  
Trial success was defined as the posterior probability that the PTB rate in the control arm is 
bigger than that in the experimental arm is greater than a cutoff value 𝛿: Pr(𝑃𝑐 > 𝑃𝑡|𝑑𝑎𝑡𝑎) > 𝛿. 
In simulations the power function is defined as the average trial success rate across simulations. 
In the null scenario both the control arm and the experimental arm have overall PTB rates of 8% 
and the average success rate is the Type I error rate. Since we have four subgroups, the overall 
Type I error rate is 1 − ∏ (1 − 𝛼𝑖
4
𝑖=1 ), where 𝛼𝑖 is the Type I error rate for the 𝑖
𝑡ℎ group. In the 
null scenario, both the control and experimental arms have the same structure in their subgroups. 
The four risk groups have PTB rates of 4%, 6%, 10%, and 12% in both arms. We tuned the 𝛿 
value in each method separately to ensure the overall Type I error rate is close to 0.05. The 𝛿 
values for the logistic model, independent model, hierarchical model, and dynamic model are 
0.993, 0.985, 0.985, and 0.98 respectively.  
In the first scenario we examined the situation where the overall PTB rate is 8% in the 
control arm and 4% in the experimental arm, indicating a large overall treatment effect. Within 
this setting, we tried different structure of PTB rates in the experimental arm to mimic different 
subgroup effects (Table 4.2). First we simulated a situation where the resulting rate in the 
experimental arm is quite linear in four subgroups: 2%, 3%, 5%, and 6% correspondingly. In this 
situation, each subgroup experienced a 50% reduction in PTB rate. Second we simulated a 
situation where the resulting rate in the experimental arm is flat in all four subgroups: all 4%. In 
this situation, there is no effect in the first subgroup and the last group has the biggest treatment 
effect. Since the first group has no effect at all, the average success rate we obtained for this 
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subgroup is a Type I error rate for this subgroup analysis. Thirdly we simulated a situation where 
the resulting rates in subgroups in the experimental arm are non-linear: 1%, 6%, 3%, and 6% 
correspondingly. We created a situation where the second subgroup has no treatment effect while 
the other three groups have treatment effects. Therefore the average success rate we obtained 
from the second subgroup is the Type I error rate for this group. We noticed that the naïve 
logistic model introduced exploded Type I error rate in this situation while the other three 
models had reasonable Type I error rates. The Type I error rates in the second subgroup under 
this situation for logistic, independent, hierarchical, and dynamic linear models are 0.732, 0.006, 
0.011, and 0.055 respectively. This shows the logistic model is not flexible in modeling 
situations where subgroup effects are not linear. We excluded logistic model in our following 
comparisons due to this inflexibility and the unintended explosion in Type I error rate in 
subgroup analysis.  
In the comparison of the other three models, we focused on power in subgroup analysis. 
Dynamic linear model has the highest power in subgroup analysis in all situations except for the 
first subgroup in the non-linear situation (Table 4.3). In the non-linear scenario, the proportions 
in the second group are 0.06 for both control and treatment arm. In this case, dynamic linear 
model has a slightly higher Type I error rate than other models but the error rate is still 
acceptable (Table 4.3). The dynamic linear model has the highest power in capturing the most 
affected group in all three situations. This is important because it represents the capability to 
identify or confirm the most beneficial subgroup. In the situation where the rates in the four 
groups of the experimental arm are linear, the power to capture the most affected subgroup in 
independent, hierarchical, and dynamic linear models is 0.548, 0.578, and 0.595 respectively. A 
regular chi-square test with Bonferroni adjustment has a power of 0.541 to capture the most 
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affected subgroup. In the situation where the rates in the four groups in the experimental arm are 
flat, the power to capture the most affected subgroup in independent, hierarchical, and dynamic 
linear models is 0.879, 0.891, and 0.917 respectively. The chi-square test has a power of 0.857 to 
capture the most affected subgroup. In the situation where the rates in the four groups in the 
experimental arm are non-linear, the power to capture the most affected subgroup in 
independent, hierarchical, and dynamic linear models is 0.848, 0.861, and 0.889 respectively. 
The chi-square test has a power of 0.827 in capturing the most affected subgroup. In a nutshell, 
the dynamic linear model increases power to capture the most affected subgroup compared to the 
other three methods where the overall treatment effect is large (Table 4.3). In addition to 
providing the power to capture the most affected group, the dynamic linear model appears to be 
powerful and robust in other subgroup analysis (Figure 4.1- Figure 4.3). 
 
 





Figure 4.2: Power analysis for flat subgroup effects in treatment arm in scenario 1 
 




In the second scenario setting we examined the situations where the overall PTB rate is 8% 
in the control arm and 6% in the experimental, indicating a small overall treatment effect. Again, 
we tried different structure of PTB rates in the experimental arm to mimic different subgroup 
effects (Table 4.2). In the first situation the rates in the four groups in the experimental arm are 
linear or ordinal: 4%, 5%, 7%, and 8% respectively. In the second situation the rates in the four 
groups in the experimental arm are flat:  all 6%. In this situation, there is no effect in the second 
subgroup and a negative effect in the first subgroup. In the last situation the rates in the four 
groups in the experimental arm are non-linear: 1%, 6%, 6%, and 11% respectively. We created a 
situation where the second subgroup had no treatment effect while the other three groups had 
treatment effects, but the effects varied among the three groups. Therefore the average success 
rate we obtained from the second subgroup is the Type I error rate for this group. The Type I 
error rates in the second subgroup under this situation for logistic, independent, hierarchical, and 
dynamic linear models are 0.487, 0.009, 0.013, and 0.031 respectively. The naïve logistic model 
exploded the Type I error rate in this situation while the other three models had reasonable Type 
I error rate. Again this shows the inflexibility of the logistic model when the group rates are not 
linear. 
The results of subgroup power analysis were summarized in Table 4.4. In the situation 
where the experimental arm subgroup rates are linear, the power to capture the most affected 
subgroup in independent, hierarchical, and dynamic linear models is 0.254, 0.253, and 0.258 
respectively. A regular chi-square test with Bonferroni adjustment has a power of 0.226 to 
capture the most affected subgroup. In the situation where the treatment arm group rates are flat, 
the power to capture the most affected subgroup in independent, hierarchical, and dynamic linear 
models is 0.555, 0.551, and 0.628 respectively. The chi-square test has a power of 0.541 to 
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capture the most affected subgroup. In the second group analysis in the flat situation, the 
experimental effect is negative. Independent, hierarchical, and dynamic linear models perform 
well but the chi-square test cannot capture this trend unless we discern the results from 
comparing the control and experimental arms (Table 4.4). In the situation where the 
experimental arm group rates are non-linear, the power to capture the most affected subgroup in 
independent, hierarchical, and dynamic linear models is 0.32, 0.461, and 0.304 respectively. The 
chi-square test has a power of 0.462 to capture the most effected subgroup. Therefore the chi-
square test and the hierarchical model perform well to capture the most affected group when the 
resulting subgroup rates are nonlinear (Table 4.4). When the resulting subgroup rates are quite 
linear or flat, the dynamic linear model still outperforms the other three methods. In other 
subgroup analysis, the dynamic linear model appears to be robust and powerful (Figure 4.4 – 
Figure 4.6 ).  
 




Figure 4.5: Power analysis for flat subgroup effects in treatment arm in scenario 2 
 
Figure 4.6: Power analysis for nonlinear subgroup effects in treatment arm in scenario 2 
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4.6 Sensitivity Analysis and Discussion  
We did a sensitivity analysis using 500 subjects per group. The comparisons between the 
statistical models remained similar with increased capability to confirm futility or success of 
subgroups (Table 4.3 and Table 4.4). We assumed ordinal risk subgroups in the control arm have 
equal sample sizes. The general population may have unequal-sized strata for similar ordinal risk 
levels. However, in clinical trial designs, it is still possible to selectively include participants to 
create balanced numbers in each subgroup. The main advantage is that when sample size is 
predetermined and equal in subgroups, the most affected subgroups have the highest treatment 
effects. Predetermined subgroup sample sizes decrease the risk of insufficient statistical power at 
the end of study (Padmanabhan, 2014). At the current stage of subgroup analysis, it is not 
necessary to meet the power requirement in general statistical analysis.  Once the most affected 
subgroups are identified through efficient designs, we can “enrich” the interested subgroups, i.e., 
recruit more subjects from the interested subgroup populations and stop recruiting certain 
subgroups that are futile. The final statistical analysis will be based upon all stages’ recruitment. 
We used unanimous informative priors in our statistical models. It is desirable to use 
subgroup specific priors if previous data are available. If the subgroup data are not consistent 
with the informative priors, the result could be decreased power. 
4.7 Conclusions  
In clinical trial designs with subgroup analysis, it is important to preserve a low Type I error 
rate and improve power to capture the most affected group. Informative priors are one way to 
increase power. When informative priors from historical data are consistent with current study 
data, they represent a more powerful mechanism. Another way to increase power is through 
design selection. Designs that used independent and hierarchical models have been discussed in 
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previous studies (Berry et al., 2013). Other efficient models may exist if we have ordinal risk 
groups. We compared the dynamic linear model, independent model, hierarchical model and 
logistic model. All these models can be tuned to have desirable operating characteristics in terms 
of overall Type I error rate. When we performed subgroup analysis, the logistic model turned out 
to be inflexible and exploded the Type I error in certain subgroups analysis. The main 
comparisons were executed among the other three methods. The dynamic linear model 
outperformed the other models in most situations with various structures of subgroup effects. We 
conclude that the dynamic linear model is relatively robust and efficient. This study shows that 
when the subgroups have certain structure, more efficient designs may exist and can lead to cost 




Table 4.1: Number of preterm babies and sample sizes in completed trials 
 
  Treatment Control 
Study preterm birth Total preterm birth Total 
Denmark 1992 9 266 15 267 
England 1995 22 113 19 119 
Europe 2000 152 394 167 403 
Netherlands 1994 8 32 10 31 
USA 2003 14 142 17 149 
KUDOS 2013 12 154 13 147 
DOMINO 2010 88 1202 67 1197 
Mexico 2015 32 365 30 365 






Table 4.2: Preterm birth rates in subgroups in simulated scenarios 
Scenario/risk group  Group 1 Group 2 Group 3 Group 4 
Control arm 
8% (control arm)  4% 6% 10% 12% 
Scenario 1: Treatment arm 
4% (linear)  2% 3% 5% 6% 
4% (flat)  4% 4% 4% 4% 
4% (nonlinear)  1% 6% 3% 6% 
Scenario 2: Treatment arm 
6% (linear)  4% 5% 7% 8% 
6% (flat)  6% 6% 6% 6% 







Table 4.3: Power in subgroup analysis when the overall treatment effect is large (8% vs. 4%) 
     Control  Treatment Power  
















Group1 4% 2% 0.169 0.097 0.188 0.176 
Group2 6% 3% 0.462 0.211 0.283 0.266 
Group3 10% 5% 0.599 0.458 0.475 0.452 
Group4 12% 6% 0.595 0.548 0.578 0.541 
Flat 
Group1 4% 4% 0.017 0.007 0.019 0.013 
Group2 6% 4% 0.227 0.095 0.132 0.112 
Group3 10% 4% 0.823 0.692 0.708 0.652 
Group4 12% 4% 0.917 0.879 0.891 0.857 
Non-linear 
Group1 4% 1% 0.316 0.31 0.515 0.463 
Group2 6% 6% 0.055 0.006 0.011 0.013 
Group3 10% 3% 0.889 0.848 0.861 0.827 
Group4 12% 6% 0.702 0.592 0.624 0.541 
 
Linear 















Group2 6% 3% 0.681 0.496 0.596 0.519 
Group3 10% 5% 0.878 0.811 0.823 0.777 
Group4 12% 6% 0.889 0.866 0.887 0.860 
Flat 
Group1 4% 4% 0.023 0.012 0.029 0.013 
Group2 6% 4% 0.323 0.188 0.272 0.214 
Group3 10% 4% 0.98 0.958 0.962 0.932 
Group4 12% 4% 0.997 0.997 0.997 0.993 
Non-linear 
Group1 4% 1% 0.769 0.753 0.867 0.788 
Group2 6% 6% 0.039 0.015 0.026 0.013 
Group3 10% 3% 0.998 0.995 0.995 0.988 





Table 4.4: Power in subgroup analysis when the overall treatment effect is small (8% vs. 6%) 
     Control  Treatment Power (250 subjects/group) 
















Group1 4% 4% 0.007 0.005 0.012 0.0125 
Group2 6% 5% 0.06 0.021 0.034 0.0399 
Group3 10% 7% 0.19 0.161 0.147 0.1491 
Group4 12% 8% 0.258 0.254 0.253 0.2259 
Flat 
Group1 4% 6% 0 0 0 0.112* 
Group2 6% 6% 0.025 0.017 0.023 0.0125 
Group3 10% 6% 0.354 0.291 0.266 0.276 
Group4 12% 6% 0.628 0.555 0.551 0.541 
Non-linear 
Group1 4% 1% 0.304 0.32 0.461 0.462 
Group2 6% 6% 0.031 0.009 0.013 0.0125 
Group3 10% 6% 0.307 0.296 0.281 0.2761 
Group4 12% 11% 0.052 0.039 0.037 0.0293 
 
Linear 















Group2 6% 5% 0.085 0.055 0.08 0.061 
Group3 10% 7% 0.385 0.342 0.337 0.294 
Group4 12% 8% 0.528 0.481 0.512 0.447 
Flat 
Group1 4% 6% 0 0 0 0.214* 
Group2 6% 6% 0.013 0.012 0.017 0.013 
Group3 10% 6% 0.635 0.565 0.559 0.536 
Group4 12% 6% 0.902 0.876 0.886 0.86 
Non-linear 
Group1 4% 1% 0.764 0.748 0.84 0.788 
Group2 6% 6% 0.031 0.009 0.019 0.013 
Group3 10% 6% 0.593 0.584 0.585 0.536 
Group4 12% 11% 0.06 0.052 0.056 0.04 


















Personalized medicine is emerging in both clinical practice and clinical trials. 
Recognition that individual variability needs to be taken into account has driven the huge interest 
in ‘precision’ medicine.  The motive is to identify the individuals who benefit from the treatment 
and who do not benefit from the treatment or even suffer from hazardous effects. On the other 
hand, personalized medicine has a potential to lower the skyrocketing health care cost by 
reducing unnecessary treatment and harmful effects. This initiative requires close collaboration 
among clinicians, researchers and biostatisticians.  In 2015, President Obama launched the 
Precision Medicine Initiative, including establishing a national database of the genetic and other 
data of one million people in the United Sates. We are in the era of “big data”. The contributions 
that biostatisticians can make in the health care arena are far beyond what we have witnessed in 
the past decades.  
Personalized medicine contains efforts from the following aspects: identify the target 
population and direct the most beneficial treatment to the individuals.  This dissertation provides 
statistical suggestions in pursuing these goals.  In contrast to traditional logistic regression, this 
dissertation discussed the use of machine learning strategies and application in identifying target 
population in a binary responding variable setting. Given the fast development of computing 
power, data driven and machine learning methods are more feasible than before. With the 
establishment of gigantic databases, we can expect the rising use of data mining methods. CART 
model is one of the data mining methods. It is user-friendly and can provide straightforward 
interpretations in health care research. Clinical trials are a key research tool for advancing 
medical knowledge as well as patient care, yet they come with a staggering price tag. Efficient 
clinical trial designs help to lower the costs. This dissertation discussed statistical methods to 
improve the trial design efficiency. In many situations, clinicians are interested in a rare binary 
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event while continuous data are collected. To avoid losing power in pre-dichotomizing, this 
dissertation proposes distributional method. This dissertation further explores different 
distributional methods to identify a less biased and more powerful method to accommodate the 
rare event circumstance. For gestational age data, we proposed a three-component mixture 
normal model. Although this model increases the bias a little bit compared to binomial model, it 
promises lower variance, lower MSE and higher power in simulation studies. This model also 
outperformed the distributional model that uses logarithmic transformation. In personalized 
medicine, subgroup variation is the focus of the research. An efficient clinical trial design not 
only recognizes the subgroup differences, but also utilizes statistical models that borrow 
information across groups. Through borrowing information from previous studies and across 
groups, this dissertation discussed methods to increase the power to capture the most affected 
group as well as the power of other subgroups. We propose a dynamic linear normal model in 
this dissertation which promises a reliable and efficient design when we have ordinal risk groups.  
This dissertation has motivated some topics for future research. In this dissertation, the 
methods used to classify target population and the methods to improve statistical power in trials 
with classified subgroups are discussed in two different application studies. It is very nature to 
use the methods we discussed in Chapter 2, i.e., logistic regression models and CART to classify 
subgroups in clinical trial designs. In DHA supplementation trials, we could use existing data, 
including clinical trials data or registry data to classify patient subpopulations. The classification 
based on real data may inspire different subgroups, e.g., different risk levels etc. It will be 
interesting to see whether these will impact on our model selection. Secondly, what we have 
discussed in Chapter 4 is the first stage in an adaptive enrichment trial design. After the interim 
analysis, we can adaptively enrich certain groups with potential to succeed and drop groups with 
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no potential to succeed in next stage recruitment. If the design involves multiple stages, we will 
reconsider how to preserve Type I error rate in the clinical trial designs.  We will also consider 
sample size calculation to ensure power is guaranteed at the final stage analysis. Thirdly, we 
could consider distributional approaches in enrichment trials designs to see if it further boosts the 
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